Skip to search formSkip to main contentSkip to account menu

AC 7700

Known as: AVE8062, Combretastatin A4 Analogue AVE8062, AC7700 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Serine
analogs & derivatives

Narrower (1)

ombrabulin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments.
Tumor vasculature is an important target in cancer treatment. Two distinct vasculartargeting therapeutic strategies are applied… 
Review
2009
Review
2009
AVE8062: a new combretastatin derivative vascular disrupting agent
Angiogenesis has an essential role in promoting and supporting tumor growth and it is an important therapeutic target. The tumor… 
Highly Cited
2008
Highly Cited
2008
Early Quantitative Evaluation of a Tumor Vasculature Disruptive Agent AVE8062 Using Dynamic Contrast-Enhanced Ultrasonography
Objectives:To evaluate the early tumor vasculature disrupting effects of the AVE8062 molecule and the feasibility of dynamic… 
Review
2007
Review
2007
Small molecule vascular disrupting agents: potential new drugs for cancer treatment.
  • S. Cai
  • Recent patents on anti-cancer drug discovery
  • 2007
  • Corpus ID: 25873315
Vascular disrupting agents (VDAs) are a new class of potential anticancer drugs that selectively destroy tumor vasculature and… 
Highly Cited
2007
Highly Cited
2007
Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.
The purpose of this study was to examine the therapeutic efficacy and underlying mechanisms of action of a vascular-disrupting… 
Review
2004
Review
2004
Vascular Targeting Agents as Cancer Therapeutics
  • P. Thorpe
  • Clinical Cancer Research
  • 2004
  • Corpus ID: 1739027
Vascular targeting agents (VTAs) for the treatment of cancer are designed to cause a rapid and selective shutdown of the blood… 
Highly Cited
2003
Highly Cited
2003
Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis
We previously reported that a novel combretastatin A-4 derivative, AC7700, has remarkable antitumour effects because of an… 
Review
2002
Review
2002
The biology of the combretastatins as tumour vascular targeting agents
The tumour vasculature is an attractive target for therapy. Combretastatin A‐4 (CA‐4) and A‐1 (CA‐1) are tubulin binding agents… 
Highly Cited
2002
Highly Cited
2002
A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs
In a previous study, we used subcutaneous LY80 tumours (a subline of Yoshida sarcoma), Sato lung carcinoma, and… 
Highly Cited
1999
Highly Cited
1999
A Novel Combretastatin A‐4 Derivative, AC‐7700, Shows Marked Antitumor Activity against Advanced Solid Tumors and Orthotopically Transplanted Tumors
AC‐7700, a novel combretastatin A‐4 derivative, suppresses the growth of solid tumors by inhibiting tumor perfusion. We evaluated… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License